Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906590 · ClinicalTrials.gov registry record · Phase 2
PPMI Tau PET Imaging
A Phase 2 study, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04906590 is a Phase 2 study that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 23 participants.
The verdict
NCT04906590, a Phase 2 study, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The Assessment of Brain Tau Burden in Participants with Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging) will evaluate if \[18F\] PI-2620 facilitates better understanding of Tau deposition in the brain in Parkinson's disease (PD).
Interventions
- DRUG [18F] PI-2620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906590
The ClinicalTrials.gov registry entry for NCT04906590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] PI-2620 is the first listed.
NCT04906590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04906590 about?
NCT04906590 is a clinical study titled "PPMI Tau PET Imaging". The Assessment of Brain Tau Burden in Participants with Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging) will evaluate if \[18F\] PI-2620 facilitates better understanding of Tau deposition in the brain in Parkinson's disease (PD).
What is the current status of trial NCT04906590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2021-08-30. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT04906590?
The interventions under investigation include: [18F] PI-2620 (DRUG).
Who is sponsoring clinical trial NCT04906590?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.